Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...

GAAP Earnings Results GAAP EPS was $0.22 per diluted share, versus $0.17 in the same quarter last year. GAAP operating income for the second quarter of fiscal 2025 increased 25% to $47.4 million ...

Bio-Techne Corp. failed to get shareholder approval on its executive compensation plan. While the vote is nonbinding, a no vote is rare. Only 35% of shareholders supported the plan during the so ...

May 7 (Reuters) - Bio-Techne (TECH.O), opens new tab on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

On May 30, Wells Fargo began coverage on Bio-Techne Corporation (NASDAQ:TECH)’s stock with an “Overweight” rating and a price objective of $59.00, as reported by The Fly. The firm’s ...

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...